Navigation Links
Genmab A/S - Notice to Convene Annual General Meeting
Date:4/7/2008

world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Genmabs 2007 Annual Report
2. Genmab Announces Year End 2007 Financial Results
3. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
4. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
5. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
6. Medarex Announces Completion of Sale of Shares in Genmab A/S
7. Genmabs Financial Calendar for 2008
8. Genmab Reaches Milestones in Ofatumumab Collaboration
9. Genmab Announces HuMax-CD32b Pre-Clinical Program
10. Roche Files IND for Second Genmab Antibody
11. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... aids to weight loss and diabetes prevention, could actually ... and they do it in a surprising way: by ... the substantial population of bacteria residing in our ... and humans, were published today in Nature . ... Weizmann Institute,s Immunology Department, who led this research together ...
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/17/2014)... global consumption of squalene / squalane is expected to be ... that finds applications in various end user industries such as ... applications like high grade lubrication, and fiber coating additives. ... is regionally segregated. Sophim ( France ), Amyris ... Japan ), SeaDragon Marine Oils Ltd. ( New ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today the publication of another peer-reviewed clinical study.    ... A Multi-center Randomized Controlled Clinical Trial Evaluating the ... Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer ...
Breaking Biology Technology:Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... 18 Volcano Corporation,(Nasdaq: VOLC ), ... measurement (FM) products designed to enhance the ... disease, announced today that it,has completed its ... CardioSpectra is a privately-held company developing innovative ...
... Dec. 18 Pharmos Corporation,(Nasdaq: PARS ) ... has elected,to resign from the Company., Mr. ... instrumental in the,strategic acquisition and the subsequent integration ... Vela acquisition,Mr. Rubino has been focused on key ...
... Vice President and General Manager of facility ... prescriptions a week, FRANKLIN LAKES, N.J., Dec. 18 ... nation,s leading pharmacy benefit,managers, today announced that AllPoints at Anson ... most-advanced automated pharmacy,capping a nearly year-long search that spanned 48 ...
Cached Biology Technology:Volcano Announces Closing of CardioSpectra Acquisition 2Volcano Announces Closing of CardioSpectra Acquisition 3Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company 2Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 2Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 3Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 4Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 5
(Date:9/17/2014)... four-year project, delivering its first release in 2004. After ... several EC projects, as a part of the EC-FP7 ... to increase the general awareness of the work done ... of the Fauna Europaea results, the Biodiversity ... tools to prepare data papers for all 56 major ...
(Date:9/17/2014)... Biomedical Informatics at IMIM (Hospital del Mar Medical Research ... have recently published a study in eLife ... role in the evolution of new proteins, some of ... discovered., Ribosomes produce proteins from the instructions found in ... genome is RNA containing information for the synthesis of ...
(Date:9/17/2014)... of researchers working on a Carnegie expedition in Australia,s ... have plummeted 40% since the mid-1970s. The scientists suggest ... in this perilous slowdown. , In a quest ... the team compared current measurements of the growth rate ... similar measurements taken more than 30 years ago. Their ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Parts of genome without a known function may play a key role in the birth of new proteins 2Coral growth rate plummets in 30-year comparison 2
... collaboration with scientists at the University of California, San Diego ... switch that plays a crucial role in the development of ... issue of the journal Molecular Cell, provide a template for ... a protein called Scp1, at will. , "Scp1 is an ...
... the reach of a novel genome mapping method ... and more cost-effective tool than traditional DNA sequencing. ... Michael Waterman, USC University Professor in molecular and ... the massive amounts of data created by a ...
... 2005, 40.3 million people in the world, including 25.8 million ... the origin of HIV-1, responsible for the AIDS pandemic, has ... months ago, the team of Martine Peeters, director of research ... unit UMR 145 jointly involving the IRD and the University ...
Cached Biology News:Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3Powerful genome ID method extended to humans 2Wild gorillas carriers of a SIV virus close to the AIDS virus 2
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Request Info...
Biology Products: